ProPhase Labs, Inc. reported a significant decline in financial performance for the first quarter of 2026, with net revenues of $478,000, down from $1.4 million in the same period last year. The decrease was primarily attributed to a drop in sales from its consumer products segment, as the company did not generate any revenue from its diagnostic services, which had previously been a source of income. The cost of revenues also decreased to $311,000 from $905,000, reflecting the absence of diagnostic services and a shift in product mix. The gross profit for the quarter was $167,000, resulting in a gross margin of 34.9%, compared to 36.8% in the prior year.
The company reported a net loss of $5.4 million, or $(0.43) per share, compared to a loss of $4.7 million, or $(1.33) per share, in the first quarter of 2025. This increase in loss was influenced by higher interest expenses, which rose to $651,000 from $539,000, due to an increased balance of outstanding debt. General and administrative expenses decreased to $2.8 million from $4.1 million, primarily due to reduced personnel costs and professional fees. Research and development expenses were eliminated in the current quarter, down from $97,000 in the previous year, as the company refocused its efforts.
Strategically, ProPhase has been navigating significant operational challenges, including the cessation of its COVID-19 diagnostic testing services in May 2025 and the subsequent Chapter 11 bankruptcy filing of its diagnostic subsidiaries in September 2025. The company is currently pursuing a reorganization plan aimed at recovering unpaid insurance claims and restructuring its laboratory operations. Additionally, ProPhase is exploring the potential sale of its subsidiary, Nebula Genomics, which focuses on genomics sequencing technologies, while also continuing to develop its BE-Smart™ Esophageal Pre-Cancer Diagnostic Screening test.
As of March 31, 2026, ProPhase had total assets of $58.7 million, a decrease from $59.9 million at the end of 2025. The company reported a working capital deficit of $53 million, reflecting ongoing liquidity challenges. Management has indicated that the company’s ability to continue as a going concern is uncertain, dependent on its capacity to generate cash flows, secure additional financing, and execute strategic initiatives. The company is actively evaluating options to improve liquidity, including potential capital raises and cost reductions, but acknowledges the inherent risks and uncertainties in achieving these goals.
About ProPhase Labs, Inc.
ProPhase Labs is a diversified biotech and genomics company developing and commercializing drugs, dietary supplements, and human genomic testing services. Its core segments include genetic sequencing via Nebula Genomics, drug development through ProPhase BioPharma, and consumer health products under TK Supplements. The company focuses on early disease detection, personalized medicine, and health optimization, serving healthcare providers, consumers, and research institutions worldwide with innovative diagnostics and genomic solutions.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.